SELLAS Life Sciences Group Inc buy DerAlmanach100000
Start price
10.06.25
/
50%
€1.37
Target price
10.06.28
-
Performance (%)
8.61%
End price
14.07.25
€1.49
Summary
This prediction ended on 14.07.25 with a price of €1.49. The BUY prediction by DerAlmanach100000 finished with a performance of 8.61%. DerAlmanach100000 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| SELLAS Life Sciences Group Inc | 15.600% | 15.600% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by DerAlmanach100000 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc